News
8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

 Read the full interview:

Download DocumentDokument herunterladenSwitzerland Global EnterpriseSwitzerland Global Enterprise
10.9.20
Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

Read more
10.11.20
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more

Investors

InvestorsNews & EventsPresentations & Documents

About us

VisionHistoryLeadershipBoard of DirectorsResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer